A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Inclusion Criteria: Eyes are eligible to be included in the study only if all of the following criteria apply. Ocular-specific inclusion criteria apply to the treated eye(s), unless otherwise specified.

• Eyes that are naive to treatment with pegcetacoplan that are prescribedpegcetacoplan per routine clinical practice according to approved pegcetacoplanprescribing information (ie, the clinical decision to treat with pegcetacoplan mustbe made before study participation is discussed with the patient)

• Patient age ≥60 years

• Visual acuity better than 20/200 on Snellen chart

• Clinical diagnosis of GA of the macula secondary to AMD in one or both eyes asdetermined by the investigator using OCT and/or FAF imaging

• GA lesion meeting the following criteria as determined by the investigator'sassessment of Spectralis OCT and/or FAF images at screening:

1. Nonsubfoveal lesion(s)

2. GA lesion visualized in its entirety on the macula-centered OCT image and notcontiguous with any areas of peripapillary atrophy

3. Presence of any pattern of hyperautofluorescence in the junctional zone of GA;absence of hyperautofluorescence (ie, pattern = none) exclusionary

• Adequate clarity of ocular media and adequate pupillary dilation and fixation topermit the collection of good quality images as determined by the investigator

• Patient willing and able to give informed consent and to comply with the studyprocedures and assessments

Exclusion Criteria: Ocular-specific exclusion criteria apply to the study eye(s) only, unless otherwise specified.

• GA secondary to a condition other than AMD such as Stargardt disease, cone roddystrophy, or toxic maculopathies like Plaquenil maculopathy in either eye

• Active, suspected, or history of intraocular inflammation in either eye at screeningor on day 1

• Any history of or active choroidal neovascularization associated with AMD or anyother cause, including any evidence of retinal pigment epithelial tears or rips inSD OCT imaging

• Presence of an active ocular disease that in the opinion of the investigatorcompromises or confounds visual function, including but not limited to uveitis andother macular diseases (eg, clinically significant epiretinal membrane, fullthickness macular hole, uncontrolled glaucoma/ocular hypertension). Conditions thatin the opinion of the investigator are benign, such as peripheral retina dystrophy,are not exclusionary

• Any prior treatment with anti-VEGF agents

• Intraocular surgery (including lens replacement surgery) within 3 months prior toscreening

• History of laser therapy in the macular region

• Aphakia or absence of the posterior capsule. Note: Yttrium aluminum garnet laserposterior capsulotomy for posterior capsule opacification done at least 60 daysprior to screening is not exclusionary.

• Any ocular condition other than GA secondary to AMD that may require surgery ormedical intervention during the study period or, in the opinion of the investigator,could compromise visual function during the study period

• Any contraindication to IVT injection

• Current ocular or periocular infection in either eye

• Intravitreal medical device placement

• Participation in any prior or current systemic experimental treatment within 6 weeksor 5 half lives of the active ingredient (whichever is longer) prior to the start ofstudy treatment or in any other investigational treatments specific to GA. Clinicaltrials solely involving observation, over-the-counter vitamins, supplements, ordiets are not exclusionary

• Medical or psychiatric conditions that, in the opinion of the investigator, makeconsistent follow-up unlikely or would make the patient an unsafe study candidate

• Known hypersensitivity to fluorescein sodium for injection or hypersensitivity topegcetacoplan or any of the excipients in pegcetacoplan solution

• History or current use of brolucizumab and/or pharmacological treatments that gainapproval for the treatment of GA